PMID- 24001083
OWN - NLM
STAT- MEDLINE
DCOM- 20131126
LR  - 20181202
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 54 Suppl 6
DP  - 2013 Sep
TI  - Treatment of Recurrent Electrographic Nonconvulsive Seizures (TRENdS) study.
PG  - 84-8
LID - 10.1111/epi.12287 [doi]
AB  - Nonconvulsive seizures (NCS) and nonconvulsive status epilepticus (NCSE) are 
      electrographic seizures (ESz) that are not associated with overt clinical seizure 
      activity. NCS are distinct ESz, whereas NCSE has ongoing, continuous 
      electrographic seizure activity. Both are common in critically ill patients 
      admitted to hospital intensive care units (ICUs), and studies have shown that 
      about 20% of ICU patients undergoing continuous electroencephalography (cEEG) 
      monitoring will have NCS/NCSE. Although the treatment for convulsive SE is well 
      established, there is no clear consensus for the treatment of NCS/NCSE. 
      Antiepileptic drugs (AEDs), such as phenytoin (PHT) and fosphenytoin (fPHT), used 
      in convulsive SE are also used to treat NCS/NCSE despite lack of data for their 
      appropriateness for these conditions. Recent studies have shown that very 
      aggressive treatment of NCSss/NCSE can lead to worse outcomes because the AEDs 
      used can have significant adverse effects. Recently, several intravenous (IV) 
      AEDs have become available for substitution therapy when their oral use is not 
      possible. There are retrospective case reports and case series that suggest that 
      these AEDs may be beneficial for treatment of NCS/NCSE. The Treatment of 
      Recurrent Electrographic Nonconvulsive Seizures (TRENdS) Study will compare the 
      efficacy and tolerability of fPHT and lacosamide in patients having NCS as noted 
      by cEEG monitoring. The study is currently open to recruitment and has 13 sites 
      in the United States. A total of 200 subjects will be randomized, 100 to each 
      treatment arm.
CI  - Wiley Periodicals, Inc. (c) 2013 International League Against Epilepsy.
FAU - Husain, Aatif M
AU  - Husain AM
AD  - Department of Medicine (Neurology), Duke University Medical Center and 
      Neurodiagnostic Center, Veterans Affairs Medical Center, Durham, NC 27710, U.S.A. 
      aatif.husain@duke.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Acetamides)
RN  - 0 (Anticonvulsants)
RN  - 563KS2PQY5 (Lacosamide)
RN  - 6158TKW0C5 (Phenytoin)
RN  - B4SF212641 (fosphenytoin)
SB  - IM
MH  - Acetamides/therapeutic use
MH  - Anticonvulsants/administration & dosage/*therapeutic use
MH  - Electroencephalography/methods
MH  - Humans
MH  - Lacosamide
MH  - Monitoring, Physiologic/methods
MH  - Phenytoin/analogs & derivatives/therapeutic use
MH  - Retrospective Studies
MH  - Secondary Prevention
MH  - Status Epilepticus/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Continuous EEG monitoring
OT  - Electrographic seizures
OT  - Fosphenytoin
OT  - Lacosamide
OT  - Nonconvulsive seizures
EDAT- 2013/09/06 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/09/05 06:00
PHST- 2013/09/05 06:00 [entrez]
PHST- 2013/09/06 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 10.1111/epi.12287 [doi]
PST - ppublish
SO  - Epilepsia. 2013 Sep;54 Suppl 6:84-8. doi: 10.1111/epi.12287.